NCT02308943: Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
|
|
| Not yet recruiting | 1 | 90 | US | Cabozantinib S-malate, BMS-907351, Cometriq, XL184, Nivolumab, anti-PD-1 human monoclonal antibody MDX-1106, BMS-936558, MDX-1106, ONO-4538, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Adult Solid Neoplasm, Malignant Reproductive System Neoplasm, Malignant Urinary System Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Progressive Neoplastic Disease, Recurrent Bladder Carcinoma, Recurrent Urethra Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma | 08/17 | | | |
NCT00915993: MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer |
|
|
| Recruiting | N/A | 40 | US | sunitinib malate, mutation analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging | University of Pennsylvania, National Cancer Institute (NCI) | Kidney Cancer | 05/11 | | | |